REPORT ID 6732

Global Multiple Sclerosis (MS) Drugs Market Professional Survey Report 2017

Publish Date
26-Dec-17
Pages
112
Format
Electronic (PDF)

This report studies Multiple Sclerosis (MS) Drugs in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering
    Bayer AG
    Bayhill Therapeutics
    Biogen Idec
    Cinnagen
    Daiichi Sankyo
    Eli Lilly
    Fast Forward Llc
    Antisense Therapeutics
    Apitope
    Five Prime Therapeutics
    Genmab
    Artielle Immunotherapeutics
    Genzyme
    Glaxosmithkline
    Gw Pharmaceuticals
    Innate Immunotherapeutics

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
    Copaxone (Glatiramer Acetate, Copolymer 1)
    Novantrone (Mitoxantrone)
    Gilenya (Fingolimod, Fty720)
    Aubagio (Teriflunomide)
    Tecfidera (Dimethyl Fumarate)
    Firategrast (Sb683699, T-0047)
    Siponimod (Baf312)
    Others

By Application, the market can be split into
    RRMS
    SPMS
    PPMS
    PRMS

By Regions, this report covers (we can add the regions/countries as you want)
    North America
    China
    Europe
    Southeast Asia
    Japan
    India

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

Global Multiple Sclerosis (MS) Drugs Market Professional Survey Report 2017
1 Industry Overview of Multiple Sclerosis (MS) Drugs
    1.1 Definition and Specifications of Multiple Sclerosis (MS) Drugs
        1.1.1 Definition of Multiple Sclerosis (MS) Drugs
        1.1.2 Specifications of Multiple Sclerosis (MS) Drugs
    1.2 Classification of Multiple Sclerosis (MS) Drugs
        1.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)
        1.2.2 Novantrone (Mitoxantrone)
        1.2.3 Gilenya (Fingolimod, Fty720)
        1.2.4 Aubagio (Teriflunomide)
        1.2.5 Tecfidera (Dimethyl Fumarate)
        1.2.6 Firategrast (Sb683699, T-0047)
        1.2.7 Siponimod (Baf312)
        1.2.8 Others
    1.3 Applications of Multiple Sclerosis (MS) Drugs
        1.3.1 RRMS
        1.3.2 SPMS
        1.3.3 PPMS
        1.3.4 PRMS
    1.4 Market Segment by Regions
        1.4.1 North America
        1.4.2 China
        1.4.3 Europe
        1.4.4 Southeast Asia
        1.4.5 Japan
        1.4.6 India

2 Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs
    2.1 Raw Material and Suppliers
    2.2 Manufacturing Cost Structure Analysis of Multiple Sclerosis (MS) Drugs
    2.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs
    2.4 Industry Chain Structure of Multiple Sclerosis (MS) Drugs

3 Technical Data and Manufacturing Plants Analysis of Multiple Sclerosis (MS) Drugs
    3.1 Capacity and Commercial Production Date of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
    3.2 Manufacturing Plants Distribution of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
    3.3 R&D Status and Technology Source of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016
    3.4 Raw Materials Sources Analysis of Global Multiple Sclerosis (MS) Drugs Major Manufacturers in 2016

4 Global Multiple Sclerosis (MS) Drugs Overall Market Overview
    4.1 2012-2017E Overall Market Analysis
    4.2 Capacity Analysis
        4.2.1 2012-2017E Global Multiple Sclerosis (MS) Drugs Capacity and Growth Rate Analysis
        4.2.2 2016 Multiple Sclerosis (MS) Drugs Capacity Analysis (Company Segment)
    4.3 Sales Analysis
        4.3.1 2012-2017E Global Multiple Sclerosis (MS) Drugs Sales and Growth Rate Analysis
        4.3.2 2016 Multiple Sclerosis (MS) Drugs Sales Analysis (Company Segment)
    4.4 Sales Price Analysis
        4.4.1 2012-2017E Global Multiple Sclerosis (MS) Drugs Sales Price
        4.4.2 2016 Multiple Sclerosis (MS) Drugs Sales Price Analysis (Company Segment)

5 Multiple Sclerosis (MS) Drugs Regional Market Analysis
    5.1 North America Multiple Sclerosis (MS) Drugs Market Analysis
        5.1.1 North America Multiple Sclerosis (MS) Drugs Market Overview
        5.1.2 North America 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
        5.1.3 North America 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
        5.1.4 North America 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis
    5.2 China Multiple Sclerosis (MS) Drugs Market Analysis
        5.2.1 China Multiple Sclerosis (MS) Drugs Market Overview
        5.2.2 China 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
        5.2.3 China 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
        5.2.4 China 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis
    5.3 Europe Multiple Sclerosis (MS) Drugs Market Analysis
        5.3.1 Europe Multiple Sclerosis (MS) Drugs Market Overview
        5.3.2 Europe 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
        5.3.3 Europe 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
        5.3.4 Europe 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis
    5.4 Southeast Asia Multiple Sclerosis (MS) Drugs Market Analysis
        5.4.1 Southeast Asia Multiple Sclerosis (MS) Drugs Market Overview
        5.4.2 Southeast Asia 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
        5.4.3 Southeast Asia 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
        5.4.4 Southeast Asia 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis
    5.5 Japan Multiple Sclerosis (MS) Drugs Market Analysis
        5.5.1 Japan Multiple Sclerosis (MS) Drugs Market Overview
        5.5.2 Japan 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
        5.5.3 Japan 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
        5.5.4 Japan 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis
    5.6 India Multiple Sclerosis (MS) Drugs Market Analysis
        5.6.1 India Multiple Sclerosis (MS) Drugs Market Overview
        5.6.2 India 2012-2017E Multiple Sclerosis (MS) Drugs Local Supply, Import, Export, Local Consumption Analysis
        5.6.3 India 2012-2017E Multiple Sclerosis (MS) Drugs Sales Price Analysis
        5.6.4 India 2016 Multiple Sclerosis (MS) Drugs Market Share Analysis

6 Global 2012-2017E Multiple Sclerosis (MS) Drugs Segment Market Analysis (by Type)
    6.1 Global 2012-2017E Multiple Sclerosis (MS) Drugs Sales by Type
    6.2 Different Types of Multiple Sclerosis (MS) Drugs Product Interview Price Analysis
    6.3 Different Types of Multiple Sclerosis (MS) Drugs Product Driving Factors Analysis
        6.3.1 Copaxone (Glatiramer Acetate, Copolymer 1) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
        6.3.2 Novantrone (Mitoxantrone) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
        6.3.3 Gilenya (Fingolimod, Fty720) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
        6.3.4 Aubagio (Teriflunomide) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
        6.3.5 Tecfidera (Dimethyl Fumarate) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
        6.3.6 Firategrast (Sb683699, T-0047) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
        6.3.7 Siponimod (Baf312) of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
        6.3.8 Others of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis

7 Global 2012-2017E Multiple Sclerosis (MS) Drugs Segment Market Analysis (by Application)
    7.1 Global 2012-2017E Multiple Sclerosis (MS) Drugs Consumption by Application
    7.2 Different Application of Multiple Sclerosis (MS) Drugs Product Interview Price Analysis
    7.3 Different Application of Multiple Sclerosis (MS) Drugs Product Driving Factors Analysis
        7.3.1 RRMS of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
        7.3.2 SPMS of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
        7.3.3 PPMS of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis
        7.3.4 PRMS of Multiple Sclerosis (MS) Drugs Growth Driving Factor Analysis

8 Major Manufacturers Analysis of Multiple Sclerosis (MS) Drugs
    8.1 Bayer AG
        8.1.1 Company Profile
        8.1.2 Product Picture and Specifications
            8.1.2.1 Product A
            8.1.2.2 Product B
        8.1.3 Bayer AG 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.1.4 Bayer AG 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
    8.2 Bayhill Therapeutics
        8.2.1 Company Profile
        8.2.2 Product Picture and Specifications
            8.2.2.1 Product A
            8.2.2.2 Product B
        8.2.3 Bayhill Therapeutics 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.2.4 Bayhill Therapeutics 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
    8.3 Biogen Idec
        8.3.1 Company Profile
        8.3.2 Product Picture and Specifications
            8.3.2.1 Product A
            8.3.2.2 Product B
        8.3.3 Biogen Idec 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.3.4 Biogen Idec 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
    8.4 Cinnagen
        8.4.1 Company Profile
        8.4.2 Product Picture and Specifications
            8.4.2.1 Product A
            8.4.2.2 Product B
        8.4.3 Cinnagen 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.4.4 Cinnagen 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
    8.5 Daiichi Sankyo
        8.5.1 Company Profile
        8.5.2 Product Picture and Specifications
            8.5.2.1 Product A
            8.5.2.2 Product B
        8.5.3 Daiichi Sankyo 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.5.4 Daiichi Sankyo 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
    8.6 Eli Lilly
        8.6.1 Company Profile
        8.6.2 Product Picture and Specifications
            8.6.2.1 Product A
            8.6.2.2 Product B
        8.6.3 Eli Lilly 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.6.4 Eli Lilly 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
    8.7 Fast Forward Llc
        8.7.1 Company Profile
        8.7.2 Product Picture and Specifications
            8.7.2.1 Product A
            8.7.2.2 Product B
        8.7.3 Fast Forward Llc 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.7.4 Fast Forward Llc 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
    8.8 Antisense Therapeutics
        8.8.1 Company Profile
        8.8.2 Product Picture and Specifications
            8.8.2.1 Product A
            8.8.2.2 Product B
        8.8.3 Antisense Therapeutics 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.8.4 Antisense Therapeutics 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
    8.9 Apitope
        8.9.1 Company Profile
        8.9.2 Product Picture and Specifications
            8.9.2.1 Product A
            8.9.2.2 Product B
        8.9.3 Apitope 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.9.4 Apitope 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
    8.10 Five Prime Therapeutics
        8.10.1 Company Profile
        8.10.2 Product Picture and Specifications
            8.10.2.1 Product A
            8.10.2.2 Product B
        8.10.3 Five Prime Therapeutics 2016 Multiple Sclerosis (MS) Drugs Sales, Ex-factory Price, Revenue, Gross Margin Analysis
        8.10.4 Five Prime Therapeutics 2016 Multiple Sclerosis (MS) Drugs Business Region Distribution Analysis
    8.11 Genmab
    8.12 Artielle Immunotherapeutics
    8.13 Genzyme
    8.14 Glaxosmithkline
    8.15 Gw Pharmaceuticals
    8.16 Innate Immunotherapeutics

9 Development Trend of Analysis of Multiple Sclerosis (MS) Drugs Market
    9.1 Global Multiple Sclerosis (MS) Drugs Market Trend Analysis
        9.1.1 Global 2017-2022 Multiple Sclerosis (MS) Drugs Market Size (Volume and Value) Forecast
        9.1.2 Global 2017-2022 Multiple Sclerosis (MS) Drugs Sales Price Forecast
    9.2 Multiple Sclerosis (MS) Drugs Regional Market Trend
        9.2.1 North America 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
        9.2.2 China 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
        9.2.3 Europe 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
        9.2.4 Southeast Asia 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
        9.2.5 Japan 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
        9.2.6 India 2017-2022 Multiple Sclerosis (MS) Drugs Consumption Forecast
    9.3 Multiple Sclerosis (MS) Drugs Market Trend (Product Type)
    9.4 Multiple Sclerosis (MS) Drugs Market Trend (Application)

10 Multiple Sclerosis (MS) Drugs Marketing Type Analysis
    10.1 Multiple Sclerosis (MS) Drugs Regional Marketing Type Analysis
    10.2 Multiple Sclerosis (MS) Drugs International Trade Type Analysis
    10.3 Traders or Distributors with Contact Information of Multiple Sclerosis (MS) Drugs by Region
    10.4 Multiple Sclerosis (MS) Drugs Supply Chain Analysis

11 Consumers Analysis of Multiple Sclerosis (MS) Drugs
    11.1 Consumer 1 Analysis
    11.2 Consumer 2 Analysis
    11.3 Consumer 3 Analysis
    11.4 Consumer 4 Analysis

12 Conclusion of the Global Multiple Sclerosis (MS) Drugs Market Professional Survey Report 2017
    Methodology
    Analyst Introduction
    Data Source